SCHEMBL21882296

SCHEMBL21882296

CCN/C=C(\C=N)c1cc(Oc2ccc([N+](=O)[O-])nc2C)ccn1

nearest known ligand 0.34

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 8/20 0.34
▸ FLT3 P36888 2/20 0.34
▸ TGFBR1 P36897 6/20 0.33
▸ PDGFRA P16234 3/20 0.32
▸ PDGFRB P09619 2/20 0.32
▸ KDR P35968 1/20 0.31
▸ RAF1 P04049 2/20 0.30
▸ PYGL P06737 2/20 0.30
▸ PYGM P11217 2/20 0.30
▸ AXL P30530 1/20 0.30
▸ KIT P10721 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21882345 0.85 TGFBR1 (0.36) CSF1RTGFBR1PDGFRAPDGFRBKDR
SCHEMBL21882305 0.84 RAF1 (0.38) CSF1RPDGFRAPDGFRBRAF1
SCHEMBL21882310 0.84 CSF1R (0.34) CSF1RFLT3TGFBR1PDGFRAPDGFRB
SCHEMBL21882304 0.81 CSF1R (0.33) CSF1RFLT3TGFBR1PDGFRAPDGFRB
SCHEMBL21425632 0.75 TGFBR1 (0.46) CSF1RFLT3TGFBR1PDGFRAPDGFRB
SCHEMBL21882349 0.74 TGFBR1 (0.38) CSF1RTGFBR1PDGFRAPDGFRB
SCHEMBL21882344 0.73 KDR (0.40) CSF1RPDGFRAKDRRAF1
SCHEMBL16038009 0.73 CSF1R (0.52) CSF1RTGFBR1PDGFRAPDGFRBKDR
SCHEMBL16037722 0.73 CSF1R (0.45) CSF1RTGFBR1PDGFRAPDGFRBKDR
SCHEMBL21426336 0.72 TGFBR1 (0.47) CSF1RFLT3TGFBR1PDGFRAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 — — EP disclosed
EP-3632907-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
Send feedback